Challenging quarter met with margin gains, leadership transition, and focus on recovery

CS MEDICA has released its financial results for the first quarter of 2024/2025 (October–December), reflecting a quarter marked by significant supply chain delays and a temporary shift in leadership. Revenue for the period amounted to DKK 279,896, with an additional DKK 760,446 received in upfront customer payments for production.

In December, the company faced two pivotal challenges: CEO Lone Henriksen’s breast cancer diagnosis and the threat of delisting from Spotlight Stock Market. Despite these events, the company strengthened its gross margin from 38% to 47% and improved its cash position from DKK -2.18 million to DKK -0.364 million.

R&D investments rose to DKK 750 thousand to support patent protection, while total assets increased to DKK 36.3 million. The company’s stock remained among the top 3 most traded on Spotlight in 2024.

During Henriksen’s absence, Gitte Henriksen and Heidi Ahlefeldt-Laurvig assumed co-CEO responsibilities, initiating a company-wide restructuring to secure faster revenue streams, mitigate supply risk, and stabilize cash flow—laying a strong foundation for 2025.

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/
About CS MEDICA A/S
Founded in 2011, CS MEDICA is a Danish MedTech company specializing in CBD-infused treatments for autoimmune and stress-related conditions, including arthritis, psoriasis, and pain management. Operating at the intersection of the pharmaceutical and cosmetics industries, CS MEDICA delivers clinically supported products with fewer side effects, offering competitive and accessible alternatives. With MDR-approved products, cutting-edge R&D, and the benefits of CBD, the company provides innovative, safe, and effective solutions. Its capital-light business model and trusted European production partners further enhance its ability to offer high-quality treatments, setting CS MEDICA apart in the MedTech sector.